Hu Yongxian, Cui Qu, Luo Chao, Luo Yi, Shi Jimin, Huang He
Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China.
Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, 6 Tiantan Xili, Dongcheng District, Beijing 100050, China.
Blood Rev. 2016 May;30(3):179-88. doi: 10.1016/j.blre.2015.11.002. Epub 2015 Nov 25.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is potentially a curative therapeutic option for hematological malignancies. In clinical practice, transplantation associated complications greatly affected the final therapeutical outcomes. Currently, primary disease relapse, graft-versus-host disease (GVHD) and infections remain the three leading causes of a high morbidity and mortality in allo-HSCT patients. Various strategies have been investigated in the past several decades including human γδ T cell-based therapeutical regimens. In different microenvironments, human γδ T cells assume features reminiscent of classical Th1, Th2, Th17, NKT and regulatory T cells, showing diverse biological functions. The cytotoxic γδ T cells could be utilized to target relapsed malignancies, and recently regulatory γδ T cells are defined as a novel implement for GVHD management. In addition, human γδ Τ cells facilitate control of post-transplantation infections and participate in tissue regeneration and wound healing processes. These features potentiate γδ T cells a versatile therapeutical agent to target transplantation associated complications. This review focuses on insights of applicable potentials of human γδ T cells reconciling complications associated with allo-HSCT. We believe an improved understanding of pertinent γδ T cell functions would be further exploited in the design of innovative immunotherapeutic approaches in allo-HSCT, to reduce mortality and morbidity, as well as improve quality of life for patients after transplantation.
异基因造血干细胞移植（allo-HSCT）可能是治疗血液系统恶性肿瘤的一种治愈性疗法。在临床实践中，移植相关并发症极大地影响了最终的治疗效果。目前，原发性疾病复发、移植物抗宿主病（GVHD）和感染仍然是allo-HSCT患者高发病率和死亡率的三大主要原因。在过去几十年中，人们研究了各种策略，包括基于人γδ T细胞的治疗方案。在不同的微环境中，人γδ T细胞具有类似于经典Th1、Th2、Th17、NKT和调节性T细胞的特征，表现出多种生物学功能。细胞毒性γδ T细胞可用于靶向复发的恶性肿瘤，最近调节性γδ T细胞被定义为管理GVHD的一种新工具。此外，人γδ T细胞有助于控制移植后感染，并参与组织再生和伤口愈合过程。这些特性使γδ T细胞成为一种多功能治疗剂，可靶向移植相关并发症。本综述重点探讨人γδ T细胞在解决allo-HSCT相关并发症方面的应用潜力。我们相信，在allo-HSCT的创新免疫治疗方法设计中，对相关γδ T细胞功能的进一步了解将得到进一步利用，以降低死亡率和发病率，并改善移植后患者的生活质量。
